Professor Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo Tokyo, Japan
Disclosure(s):
Keishi Fujio, PhD: AbbVie Pharmaceutical Research and Development: Grant Support (Ongoing), Lecture Fees (Ongoing); Asahi-Kasei: Consultant/Advisor (Ongoing), Grant Support (Ongoing), Lecture Fees (Ongoing); AstraZeneca: Grant Support (Ongoing), Lecture Fees (Ongoing); Bristol-Myers: Grant Support (Ongoing), Lecture Fees (Ongoing); Chugai: Grant Support (Ongoing), Lecture Fees (Ongoing); Daichi Sankyo: Lecture Fees (Ongoing); Eisai: Grant Support (Ongoing), Lecture Fees (Ongoing); Eli Lilly: Grant Support (Ongoing), Lecture Fees (Ongoing); Gilead: Lecture Fees (Ongoing); Novartis: Consultant/Advisor (Ongoing), Lecture Fees (Ongoing); Pfizer: Lecture Fees (Ongoing); Tanabe-Mitsubishi: Grant Support (Ongoing), Lecture Fees (Ongoing); Tsumura: Grant Support (Ongoing), Lecture Fees (Ongoing)
Learning Objectives:
Upon completion, participant will be able to discuss the genetic basis and immunological impact of OXPHOS modification of B cells in systemic lupus erythematosus.'.
Upon completion, participant will be able to explain the effect of BAFF-inhibition by belimumab to immune cell transcriptome in systemic lupus erythematosus.'.
Upon completion, participant will be able to describe the abnormality of B cell receptor repertoire indicated by IGHV gene usage in systemic lupus erythematosus.'.
